Key facts
- · Holder: Yi Shi · Percent: 11.1% · SCHEDULE 13G
- · Holder: SR One Capital Management, LLC · Percent: 9.3% · SCHEDULE 13D
- · Holder: Orbimed Advisors LLC · Percent: 14% · SCHEDULE 13D
- · Holder: BCLS Fund III Investments, LP · Percent: 6.3% · SCHEDULE 13G
ADARx Pharmaceuticals, Inc. has 4 Schedule 13D or 13G filings on record since 2026-10-01. 4 holders' latest filing reports 5% or more of common stock, par value $0.0001 per share. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Orbimed Advisors LLC | 14% | 14,913,764 | SCHEDULE 13D, 2026-10-02 | 2026-09-28 |
| Yi Shi | 11.1% | 11,858,655 | SCHEDULE 13G, 2026-10-16 | 2026-09-30 |
| SR One Capital Management, LLC | 9.3% | 9,936,661 | SCHEDULE 13D, 2026-10-05 | 2026-09-28 |
| BCLS Fund III Investments, LP | 6.3% | 6,728,970 | SCHEDULE 13G, 2026-10-01 | 2026-09-24 |
Holding shares or following this stake? See who's behind ADARx Pharmaceuticals, Inc. and the warning signs.
Free to see. No signup.
Want the whole picture on ADARx Pharmaceuticals, Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on ADARx Pharmaceuticals, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on ADARx Pharmaceuticals, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
4 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Purpose of Transaction (Item 4)
Orbimed Advisors LLC
This Statement on Schedule 13D relates to the acquisition of Shares by the Reporting Persons. The Shares acquired by the Reporting Persons were acquired for the purpose of making an investment in the Issuer and not with the intention of acquiring control of the Issuer's business on behalf of the Reporting Persons' respective advisory clients. The Reporting Persons from time to time intend to review their investment in the Issuer on the basis of various factors, including the Issuer's business, financial condition, results of operations and prospects, general economic and industry conditions, the securities markets in general and those for the Issuer's Shares in particular, as well as other developments and other investment opportunities. Based upon such review, the Reporting Persons will take such actions in the future as the Reporting Persons may deem appropriate in light of the circumstances existing from time to time. If the Reporting Persons believe that further investment in the Issuer is attractive, whether because of the market price of Shares or otherwise, they may acquire Shares or other securities of the Issuer either in the open market or in privately negotiated transactions. Similarly, depending on market and other factors, the Reporting Persons may determine to dispose of some or all of the Shares currently owned by the Reporting Persons or otherwise acquired by the Reporting Persons either in the open market or in privately negotiated transactions. Except as …The first part of Item 4 of the SCHEDULE 13D filed 2026-10-02; the filing has the rest
SR One Capital Management, LLC
The Funds acquired their respective shares for investment purposes. Depending on market conditions, its continuing evaluation of the business and prospects of the Issuer and other factors, the Funds and other Reporting Persons may dispose of or acquire additional shares of the Issuer. Except as set forth above, none of the Reporting Persons has any present plans which relate to or would result in: (a) The acquisition by any person of additional securities of the Issuer, or the disposition of securities of the Issuer; (b) An extraordinary corporate transaction, such as a merger, reorganization or liquidation, involving the Issuer or any of its subsidiaries; (c) A sale or transfer of a material amount of assets of the Issuer or any of its subsidiaries; (d) Any change in the present board of directors or management of the Issuer, including any plans or proposals to change the number or term of directors or to fill any existing vacancies on the board; (e) Any material change in the present capitalization or dividend policy of the Issuer; (f) Any other material change in the Issuer's business or corporate structure; (g) Changes in the Issuer's charter, bylaws or instruments corresponding thereto or other actions which may impede the acquisition of control of the Issuer by any person; (h) Causing a class of securities of the Issuer to be delisted from a national securities exchange or to cease to be authorized to be quoted in an inter-dealer quotation system of a …The first part of Item 4 of the SCHEDULE 13D filed 2026-10-05; the filing has the rest
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2026-10-01 | BCLS Fund III Investments, LP | 6.3% | SCHEDULE 13G |
| 2026-10-02 | Orbimed Advisors LLC | 14% | SCHEDULE 13D |
| 2026-10-05 | SR One Capital Management, LLC | 9.3% | SCHEDULE 13D |
| 2026-10-16 | Yi Shi | 11.1% | SCHEDULE 13G |
Tools for this story
Each opens in a new tab, filled in for ADARx Pharmaceuticals, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.